Pfizer Inc
Free ChatGPT may incorrectly answer drug questions, study says
Harun Ozalp | Anadolu | Getty Images The free version of ChatGPT may provide inaccurate or incomplete responses — or no answer at all — to questions related to medications, which could potentially endanger patients who use OpenAI’s viral chatbot, a new study released Tuesday suggests. Pharmacists at Long Island University who posed 39 questions […]
Read More
Pfizer’s twice-daily weight loss pill joins a long list of obesity drug flops
Sopa Images | Lightrocket | Getty Images Pfizer’s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The drugmaker on Friday said it will stop developing the twice-daily treatment, danuglipron, after obese patients taking the drug […]
Read More
Why Pfizer’s latest stumble in the obesity market is a boon for Eli Lilly
Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss pill, danuglipron, after patients in a mid-stage trial experienced […]
Read More
Stocks building the most significant moves midday: Tesla, Disney, Alibaba, Ulta Splendor and a lot more
Examine out the organizations creating headlines in midday trading. Tesla — Tesla shares slipped less than 1% as Wall Road assessed the firm’s extensive-anticipated Cybertruck pursuing a supply start occasion Thursday in Texas. Disney — Disney shares were being nearly flat soon after the leisure large reinstated its dividend at 30 cents per share amid […]
Read More
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer on Friday said it would stop developing the twice-daily version of its experimental weight loss pill after obese patients taking the drug lost weight but had trouble tolerating the drug in a mid-stage clinical study. The drugmaker observed high rates of adverse side effects, which were mostly mild and gastrointestinal, among patients. A significant […]
Read More
Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
Test tubes are seen in front of a displayed Abbvie logo in this illustration taken, May 21, 2021. Dado Ruvic | Reuters Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. Shares of ImmunoGen jumped more than 80% on Thursday, putting it on track for its highest […]
Read More
Covid vaccine rates in the U.S. are slumping — and it will be a challenge to boost them
A sign advertises Covid vaccine shots at a Walgreens Pharmacy in Somerville, Massachusetts, on Aug. 14, 2023. Brian Snyder | Reuters Three years into the Covid-19 pandemic, few Americans are rolling up their sleeves to get a Covid vaccine. Only 15.7% of U.S. adults had received the newest Covid shots from Pfizer, Moderna and Novavax […]
Read More
Tim Prepare dinner, Elon Musk, Steve Schwarzman noticed at Xi Jinping meal with U.S. CEOs
Major company leaders in the U.S. fulfill Chinese President Xi Jinping in San Francisco, California on Nov. 15, 2023. Eamon Javers, CNBC Correspondent Apple CEO Tim Prepare dinner, Tesla main Elon Musk and Blackstone’s Steve Schwarzman ended up amongst the company Wednesday night at a gala reception and meal in San Francisco for visiting Chinese […]
Read More
Pfizer wants in on the weight loss drug market – and upcoming data will be crucial for its success
CFOTO | Future Publishing | Getty Images As its Covid gains evaporate, Pfizer wants a chunk of the budding weight loss drug market. Analysts say upcoming data on Pfizer’s experimental obesity pill, danuglipron, will be crucial in determining how competitive the company can be against the space’s dominant players Eli Lilly and Novo Nordisk. Those […]
Read More
Eli Lilly says supply of blockbuster diabetes drug Mounjaro has improved in U.S.
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, March 29, 2023. George Frey | Reuters Eli Lilly on Thursday said supply of its blockbuster diabetes drug Mounjaro has improved in the U.S. after months of widespread […]
Read More